IL269214B - Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors - Google Patents

Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors

Info

Publication number
IL269214B
IL269214B IL269214A IL26921419A IL269214B IL 269214 B IL269214 B IL 269214B IL 269214 A IL269214 A IL 269214A IL 26921419 A IL26921419 A IL 26921419A IL 269214 B IL269214 B IL 269214B
Authority
IL
Israel
Prior art keywords
quinoline derivatives
lrrk2 inhibitors
novel imidazo
imidazo
novel
Prior art date
Application number
IL269214A
Other languages
English (en)
Hebrew (he)
Other versions
IL269214A (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL269214A publication Critical patent/IL269214A/en
Publication of IL269214B publication Critical patent/IL269214B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL269214A 2017-03-10 2019-09-09 Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors IL269214B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469756P 2017-03-10 2017-03-10
US201862629152P 2018-02-12 2018-02-12
PCT/IB2018/051439 WO2018163066A1 (en) 2017-03-10 2018-03-06 Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors

Publications (2)

Publication Number Publication Date
IL269214A IL269214A (en) 2019-11-28
IL269214B true IL269214B (en) 2022-03-01

Family

ID=61683855

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269214A IL269214B (en) 2017-03-10 2019-09-09 Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors

Country Status (13)

Country Link
US (1) US11312713B2 (enExample)
EP (1) EP3592741B1 (enExample)
JP (1) JP7219223B2 (enExample)
KR (1) KR102582626B1 (enExample)
CN (1) CN111051304B (enExample)
AU (1) AU2018230236B2 (enExample)
BR (1) BR112019018688A2 (enExample)
CA (1) CA3056030A1 (enExample)
IL (1) IL269214B (enExample)
MX (1) MX2019010756A (enExample)
SG (2) SG10202110112TA (enExample)
TW (1) TWI701246B (enExample)
WO (1) WO2018163066A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996932B (zh) 2020-05-06 2025-08-01 法国施维雅药厂 新的大环lrrk2激酶抑制剂
AU2022239815A1 (en) 2021-03-18 2023-09-21 Les Laboratoires Servier Macrocyclic lrrk2 kinase inhibitors
WO2023220238A1 (en) * 2022-05-12 2023-11-16 Interline Therapeutics, Inc. Lrrk2 inhibitors
AU2023269638A1 (en) * 2022-05-12 2024-11-14 Interline Therapeutics, Inc. Lrrk2 inhibitors
CN115728413A (zh) * 2022-11-09 2023-03-03 内蒙古帕默康创医疗仪器有限公司 舍曲林血药浓度的定量分析方法
CN116879450A (zh) * 2023-07-25 2023-10-13 江苏汉邦科技股份有限公司 一种利用超临界流体色谱系统分离纯化芦可替尼前体的方法
CN118440041B (zh) * 2024-07-02 2024-09-27 苏州凯瑞医药科技有限公司 一种手性4-氨基-3-羟基四氢吡喃的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
CA1335996C (en) * 1988-02-16 1995-06-20 Susumu Takada 2-substituted carbonylimidazo¬4,5-c|quinolines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
EP3150633A1 (en) 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
AU2002239764B2 (en) 2000-11-03 2007-06-21 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
JP2007519707A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−３受容体モジュレーター
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
ITMI20070890A1 (it) 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
US8895581B2 (en) * 2010-05-17 2014-11-25 Boehringer Ingelheim International Gmbh 1H-imidazo[4,5-c]quinolines
JP5781611B2 (ja) 2010-09-02 2015-09-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｒｒｋ２キナーゼ阻害剤としての２−（ベンジルオキシ）ベンズアミド類
US9233977B2 (en) 2010-10-29 2016-01-12 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
ITTO20130694A1 (it) * 2013-08-14 2015-02-15 Umbra Meccanotecnica Giunto washpipe per un impianto di perforazione petrolifera
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016108130A1 (en) 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
JP2019517580A (ja) 2016-06-01 2019-06-24 ハロルド・リチャード・ヘルストロムＨａｒｏｌｄ Ｒｉｃｈａｒｄ ＨＥＬＬＳＴＲＯＭ 副交感神経薬および抗交感神経薬でのドライアイ疾患の処置
US11161844B2 (en) * 2017-03-10 2021-11-02 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives

Also Published As

Publication number Publication date
CN111051304B (zh) 2022-12-27
EP3592741B1 (en) 2023-02-15
CA3056030A1 (en) 2018-09-13
AU2018230236A1 (en) 2019-10-31
IL269214A (en) 2019-11-28
JP7219223B2 (ja) 2023-02-07
TW201900642A (zh) 2019-01-01
JP2020510046A (ja) 2020-04-02
US11312713B2 (en) 2022-04-26
TWI701246B (zh) 2020-08-11
CN111051304A (zh) 2020-04-21
EP3592741A1 (en) 2020-01-15
BR112019018688A2 (pt) 2020-04-07
KR102582626B1 (ko) 2023-09-22
SG10202110112TA (en) 2021-10-28
SG11201908322WA (en) 2019-10-30
WO2018163066A1 (en) 2018-09-13
AU2018230236B2 (en) 2022-05-19
RU2019131727A (ru) 2021-04-12
NZ757971A (en) 2024-12-20
US20210355117A1 (en) 2021-11-18
MX2019010756A (es) 2020-01-20
RU2019131727A3 (enExample) 2021-04-26
KR20190138793A (ko) 2019-12-16

Similar Documents

Publication Publication Date Title
IL257886B (en) History of imidazo[5,4-c]quinoline and imidazo[5,4-c][5,1]naphthyridine as lrrk2 inhibitors
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
ZA201800771B (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
ZA201808257B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
PT3371185T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
PT3712152T (pt) Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
EP3172214A4 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
EP3154970A4 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
IL251164B (en) Imidazo[4,5–c]pyridine derivatives as inhibitors of ssao
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
IL258341A (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
IL251166A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
IL269215A (en) Disubstituted imidazole[4,5-C]quinoline derivatives
EP3302060A4 (en) Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase
HK40012863A (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
HK40041290A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors